➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
AstraZeneca
Dow
Baxter
McKinsey

Last Updated: March 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GALANTAMINE HYDROBROMIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Galantamine Hydrobromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00077727 A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2003-03-01 The purpose of this study is to determine if adding extended-release galantamine hydrobromide, compared with adding placebo, to current atypical antipsychotic therapy is well tolerated and effective in improving cognitive impairment in patients with schizophrenia.
NCT00216593 Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study Completed Janssen Pharmaceutica N.V., Belgium Phase 3 2003-12-01 The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
NCT00236431 A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 2001-05-01 The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Galantamine Hydrobromide

Condition Name

Condition Name for Galantamine Hydrobromide
Intervention Trials
Dementia 4
Alzheimer Disease 4
Alzheimer's Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Galantamine Hydrobromide
Intervention Trials
Alzheimer Disease 6
Cognition Disorders 4
Dementia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Galantamine Hydrobromide

Trials by Country

Trials by Country for Galantamine Hydrobromide
Location Trials
United States 3
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Galantamine Hydrobromide
Location Trials
Tennessee 1
Connecticut 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Galantamine Hydrobromide

Clinical Trial Phase

Clinical Trial Phase for Galantamine Hydrobromide
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Galantamine Hydrobromide
Clinical Trial Phase Trials
Completed 11
Terminated 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Galantamine Hydrobromide

Sponsor Name

Sponsor Name for Galantamine Hydrobromide
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4
Actavis Inc. 2
Dr. Reddy's Laboratories Limited 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Galantamine Hydrobromide
Sponsor Trials
Industry 12
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Mallinckrodt
Merck
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.